YM BioSciences rises on PhI/II results showing promise for JAK1/JAK2 inhibitor for myelofibrosis
This article was originally published in Scrip
Executive Summary
YM BioSciences reported updated Phase I/II data for its oral JAK1/JAK2 inhibitor CYT387 as a potential treatment for myelofibrosis (MF) in a 12 December poster session at the annual meeting of the American Society of Hematology in San Diego.